Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Intellia Therapeutics, Inc. - Common Stock
(NQ:
NTLA
)
10.68
-0.41 (-3.70%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 31, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Intellia Therapeutics, Inc. - Common Stock
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
21
22
Next >
Expert Ratings for Intellia Therapeutics
↗
January 24, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023
↗
January 24, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
↗
January 20, 2023
Friday saw 23 companies set new 52-week lows.
Via
Benzinga
The Latest Analyst Ratings for Intellia Therapeutics
↗
January 04, 2023
Via
Benzinga
Analyst Ratings for Intellia Therapeutics
↗
December 02, 2022
Via
Benzinga
Intellia's Hereditary Angioedema Candidate Shows Reduction In Associated Biomarkers, Attack Rates
↗
November 14, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2023
↗
January 19, 2023
Via
Benzinga
2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years
↗
January 07, 2023
Both are hoping to use the latest gene editing technology to make the lucrative therapies of tomorrow.
Via
The Motley Fool
1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now)
↗
December 30, 2022
Both stocks have fallen brutally this year, but only one has a chance to recover soon.
Via
The Motley Fool
Recap: Intellia Therapeutics Q3 Earnings
↗
November 03, 2022
Intellia Therapeutics (NASDAQ:NTLA) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
7 Analysts Have This to Say About Intellia Therapeutics
↗
October 11, 2022
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings:
Via
Benzinga
3 Mid-Caps That Could Double in 2023
December 15, 2022
Mid-cap land has long been regarded as the ‘sweet spot’ for equity investors. Here are three mid-caps Wall Street sees as two-baggers over the next 12 months.
Via
MarketBeat
7 ‘Next Big Things’ for Investors to Buy for 2023
↗
December 13, 2022
The next big thing for investors in 2023 is buying companies with revenue expansion amid what could be a painful economic slowdown.
Via
InvestorPlace
Ulta Beauty To Rally Around 22%? Here Are 10 Other Price Target Changes For Friday
↗
December 02, 2022
Via
Benzinga
NTLA Stock Falls as Intellia Therapeutics Announces Public Offering
↗
December 01, 2022
Intellia Therapeutics (NTLA) stock is falling hard on Thursday after the company announced a public stock offering of 6.6 million shares.
Via
InvestorPlace
Cathie Wood Has Bet Big On These 10 Stocks; Here's How They're Performing
↗
November 28, 2022
Here's how Ark Invest's top holdings have performed in 2022.
Via
Investor's Business Daily
Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%
↗
November 15, 2022
Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to $129. Intellia Therapeutics shares fell 3% to close at $53.30 on Monday.
Via
Benzinga
Earnings Preview For Intellia Therapeutics
↗
November 02, 2022
Intellia Therapeutics (NASDAQ:NTLA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
↗
November 01, 2022
Upgrades
Via
Benzinga
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
↗
October 20, 2022
Despite enthusiasm in some camps, the risk of potential cures clouds market projections.
Via
Investor's Business Daily
3 Cathie Wood Stocks to Buy and Hold for 10 Years
↗
October 19, 2022
The risks are formidable, but the chances of a massive gain are too much to pass up.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
↗
October 11, 2022
Upgrades
Via
Benzinga
The Top 5 Stocks Cathie Wood Is Buying This Week
↗
September 23, 2022
Cathie Wood announced that she would step down as portfolio manager for PRNT and IZRL. That hasn't stopped her from making her usual buys.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022
↗
September 21, 2022
Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago...
Via
Benzinga
5 Top Stocks Cathie Wood Is Buying Right Now
↗
September 19, 2022
Cathie Wood's ARKK is down over 50% YTD, although the fund manager is still continuing her purchases of high conviction companies.
Via
InvestorPlace
SVB Leerink Maintains Outperform Rating for Intellia Therapeutics: Here's What You Need To Know
↗
September 19, 2022
SVB Leerink has decided to maintain its Outperform rating of Intellia Therapeutics (NASDAQ:NTLA) and raise its price target from $152.00 to $158.00. Shares of Intellia Therapeutics are trading down...
Via
Benzinga
What 4 Analyst Ratings Have To Say About Intellia Therapeutics
↗
September 19, 2022
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings:
Via
Benzinga
This Analyst Cuts PT On Adobe, Plus Barclays Predicts $240 For FedEx
↗
September 19, 2022
Wells Fargo lowered the price target for Adobe Inc. (NASDAQ: ADBE) from $425 to $310. Adobe shares fell 1.2% to $296.04 in pre-market trading.
Via
Benzinga
Why Is Applied Optoelectronics (AAOI) Stock Up 35% Today?
↗
September 16, 2022
Applied Optoelectronics (AAOI) stock is climbing higher on Friday after the company revealed a $150 million asset sale and new brand launch.
Via
InvestorPlace
Why Is Esports Entertainment (GMBL) Stock Down 45% Today?
↗
September 16, 2022
Esports Entertainment (GMBL) stock is falling hard on Friday after the company revealed the pricing of a public stock offering.
Via
InvestorPlace
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
21
22
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.